Novavax, Inc. (NVAX) |
|
7.24 0.08 (1.12%)
|
09-29 16:00 |
|
Open: |
7.29 |
Pre. Close: |
7.16 |
|
High:
|
7.68 |
Low:
|
7.16 |
|
Volume:
|
8,089,672 |
Market Cap:
|
731(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:29:21 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 10.43 One year: 12.03 |
| Support: |
Support1: 6.71 Support2: 5.59 |
| Resistance: |
Resistance1: 8.93 Resistance2: 10.3 |
| Pivot: |
7.39  |
| Moving Average: |
MA(5): 7.2 MA(20): 7.8
MA(100): 7.87 MA(250): 10.69 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 17.1 %D(3): 14.7 |
| RSI: |
RSI(14): 44.8 |
| 52-week: |
High: 25.65 Low: 5.61 |
| Average Vol(K): |
3-Month: 9,428 (K) 10-Days: 7,881 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NVAX ] has closed above bottom band by 38.8%. Bollinger Bands are 42.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.69 - 7.72 |
7.72 - 7.76 |
|
Low:
|
7.08 - 7.12 |
7.12 - 7.15 |
|
Close:
|
7.18 - 7.24 |
7.24 - 7.3 |
|
Company Description |
|
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. |
Headline News |
Sun, 01 Oct 2023
Novavax (NASDAQ:NVAX) Trading Up 4.5% - Defense World
Thu, 28 Sep 2023
Novavax Inc. stock falls Thursday, underperforms market - MarketWatch
Wed, 27 Sep 2023
Premarket Mover: Novavax Inc (NVAX) Up 0.84% - InvestorsObserver
Fri, 22 Sep 2023
Novavax Inc. stock rises Friday, outperforms market - MarketWatch
Thu, 14 Sep 2023
Novavax Inc. stock outperforms market on strong trading day - MarketWatch
Mon, 11 Sep 2023
Novavax Inc Shares Down 6% After Co Says Updated Covid ... - Marketscreener.com
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
101 (M) |
| Shares Float |
82 (M) |
|
% Held by Insiders
|
0.6 (%) |
|
% Held by Institutions
|
70.6 (%) |
|
Shares Short
|
40,090 (K) |
|
Shares Short P.Month
|
36,950 (K) |
Stock Financials |
|
EPS
|
-6.91 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-8 |
|
Profit Margin (%)
|
-36.8 |
|
Operating Margin (%)
|
-38.5 |
|
Return on Assets (ttm)
|
-17.9 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
128.3 |
|
Gross Profit (p.s.)
|
-1.55 |
|
Sales Per Share
|
15.85 |
|
EBITDA (p.s.)
|
-5.74 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-654 (M) |
|
Levered Free Cash Flow
|
-273 (M) |
Stock Valuations |
|
PE Ratio
|
-1.05 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.91 |
|
Price to Sales
|
0.45 |
|
Price to Cash Flow
|
-1.12 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
